Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2025-10-31 Share Issue/Capital Cha…
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Ändring av antalet aktier och röster i Egetis Therapeutics
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement regarding a change in the number of shares and votes in Egetis Therapeutics AB due to a directed share issue. This type of corporate disclosure, which details changes in capital structure and share counts, falls under the 'Share Issue/Capital Change' category. The document is short and serves as a formal notification of this change, fitting the definition for SHA.
2025-10-31 Swedish
Egetis beviljas löpande NDA-granskning av FDA för Emcitate® (tiratricol) baserat på redan tillgängliga kliniska data
Legal Proceedings Report Classification · 100% confidence The document is a press release from Egetis Therapeutics announcing the outcome of a pre-NDA meeting with the FDA regarding their drug Emcitate. It details the regulatory pathway, clinical data plans, and includes information about an upcoming webcast. While it contains significant corporate news, it is a standard regulatory announcement (press release) regarding company operations and regulatory milestones, which falls under the RNS (Regulatory Filings) category as it does not fit into specific financial reporting or governance categories.
2025-10-23 Swedish
Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on currently available clinical data
Regulatory Filings Classification · 100% confidence The document is a press release issued by Egetis Therapeutics regarding a regulatory update from the FDA concerning the rolling NDA submission for their drug Emcitate. It details the outcome of a pre-NDA meeting, future submission timelines, and clinical trial status. It is a standard corporate regulatory announcement (RNS) that provides material information to the market, fitting the 'Regulatory Filings' category as it does not fall into specific categories like earnings releases or financial reports.
2025-10-23 English
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 183 million
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a 'directed share issue' by Egetis Therapeutics. It details the number of new shares issued, the subscription price, the total proceeds raised (SEK 183 million), the purpose of the funds, and the impact on share capital and dilution. This fits the definition of a 'Share Issue/Capital Change' (SHA) as it describes a specific capital-raising event involving the issuance of new shares.
2025-10-02 English
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission uppgående till 183 miljoner kronor
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a successful directed share issue (nyemission) by Egetis Therapeutics AB. It details the number of shares issued, the subscription price, the total capital raised, the purpose of the funds, and the involvement of institutional investors. This falls under the category of announcements regarding new share issues or capital changes.
2025-10-02 Swedish
Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares
Capital/Financing Update Classification · 100% confidence The document is a press release announcing Egetis Therapeutics' intention to conduct a 'directed share issue' (a private placement) to institutional investors. It details the purpose of the capital raise, the appointment of a bookrunner, and the legal disclaimers associated with the offering. This falls squarely under the definition of a capital/financing update, as it describes a specific fundraising activity and changes to the company's capital structure.
2025-10-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.